Evidence map›Paper›PMID 20424219›Full record

Trial reportDiabetes care2010

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition.

Mathijs C Bunck, Michaela Diamant, Bjorn Eliasson, Anja Cornér, Rimma M Shaginian, Robert J Heine, Marja-Riitta Taskinen, Hannele Yki-Järvinen, Ulf Smith

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes care, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04122716 (Synergy Effect of the Appetite Hormone GLP-1), which is not on this map. Cited by 64 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 10 pooled it
9.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04122716 phase4unknown statusstarted 2016, after this paper: background citation

Synergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized Trial

Ran2016Enrolled215Registered outcomes28Posted comparisons0ConditionsObesityArmsExercise, liraglutide
PMID 23186644PMID 26132939PMID 26284720PMID 28049736PMID 30052921PMID 27295427PMID 27633186PMID 25287751PMID 23812094PMID 11234459PMID 22436841PMID 22013105other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 10 syntheses or guidelines pooled it, 155 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Exenatide exerts a potent antiinflammatory effect.The Journal of clinical endocrinology and metabolism · 2012 · on this map
    Trial
  18. Trial
  19. Trial
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 4 countries.

Mathijs C BunckDepartment of Internal Medicine, Section of Endocrinology, Diabetes Center, VU University Medical Center, Amsterdam, the Netherlands. mcmbunck@vumc.nl
Michaela Diamant
Bjorn Eliasson
Anja Cornér
Rimma M Shaginian
Robert J Heine
Marja-Riitta Taskinen
Hannele Yki-Järvinen
Ulf Smith
Helsinki University Hospital · FIAmsterdam UMC Location VUmc · NLSahlgrenska University Hospital · SEEli Lilly (Netherlands) · NLEli Lilly (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo study the effect of exenatide on body composition and circulating cardiovascular risk biomarkers. RESEARCH DESIGN AND

methodsMetformin-treated patients with type 2 diabetes (N = 69) were randomized to exenatide or insulin glargine and treated for 1 year. Body composition was evaluated by dual-energy X-ray absorptiometry. Additionally, body weight, waist circumference, and cardiovascular biomarkers were measured.

resultsTreatment with exenatide for 1 year significantly reduced body weight, waist circumference, and total body and trunkal fat mass by 6, 5, 11, and 13%, respectively. In addition, exenatide increased total adiponectin by 12% and reduced high-sensitivity C-reactive protein by 61%. Insulin glargine significantly reduced endothelin-1 by 7%. These changes were statistically independent of the change in total body fat mass and body weight.

conclusionsExenatide treatment for 1 year reduced body fat mass and improved the profile of circulating biomarkers of cardiovascular risk. No significant changes were seen with insulin glargine except a trend for reduced endothelin-1 levels.

Indexed as

Absorptiometry, PhotonAdiponectinBody CompositionBody WeightCardiovascular DiseasesC-Reactive ProteinEndothelin-1ExenatideFemaleHumansHypoglycemic AgentsInsulin GlargineInsulin, Long-ActingMaleMiddle AgedPeptidesAdiponectinC-Reactive ProteinEndothelin-1ExenatideHypoglycemic AgentsInsulin GlargineInsulin, Long-ActingPeptidesVenoms

Identifiers

PMID20424219
PMCPMC2909051
OpenAlexW2157869836

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.